Abbott Laboratories has filed a patent for a biostimulator and biostimulator system for septal pacing. The device includes an articulation that allows the electrode axis to be directed differently from the housing axis, enabling the electrode to affix to target tissue of the interventricular septal wall when the housing is near the heart’s apex. The patent claim describes the specific components and their arrangement in the biostimulator. GlobalData’s report on Abbott Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abbott Laboratories, NSAID cancer drugs was a key innovation area identified from patents. Abbott Laboratories's grant share as of September 2023 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Biostimulator system for septal pacing with flexible articulation
A recently filed patent (Publication Number: US20230310868A1) describes a biostimulator that includes a pacing electrode, a housing, and an articulation between the electrode and the housing. The pacing electrode has an electrode axis, while the housing has an electronics compartment containing pacing circuitry that is electrically connected to the electrode. The unique feature of this biostimulator is that the electrode axis and the housing axis extend in different directions when the electrode is affixed to an interventricular septal wall and the housing is located at a ventricular apex.
The patent claims also describe additional features of the biostimulator. For example, the pacing electrode can include a helical electrode or a post electrode. The biostimulator may also include an anchor with flexible tines arranged around an anchor axis. The outer dimension of the tines is smaller than the outer dimension of the housing. An extension can be present between the housing and the pacing electrode, with a flexible portion serving as the articulation. A strain relief can be included between the distal end of the housing and the extension. The biostimulator may also have an anode spaced apart from the pacing electrode, a stabilizer with movable elements, and an attachment feature for mounting an anchor.
The patent claims also describe a biostimulator system that includes the biostimulator mounted on a transport system. The system has the same features as the individual biostimulator, including the articulation between the electrode and the housing.
The patent claims further include a method for using the biostimulator. The method involves affixing the pacing electrode to an interventricular septum and articulating the biostimulator at the articulation to direct the housing towards a ventricular apex. This ensures that the electrode axis and the housing axis extend in different directions.
In summary, the filed patent describes a biostimulator with a unique articulation between the pacing electrode and the housing. The patent claims also cover additional features such as different types of electrodes, anchors with flexible tines, extensions with flexible portions, and various methods of using the biostimulator.
To know more about GlobalData’s detailed insights on Abbott Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
